Jpmorgan Chase & CO Spruce Biosciences, Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding SPRB
# of Institutions
42Shares Held
16.9MCall Options Held
26.9KPut Options Held
59.3K-
River Vest Venture Management LLC St. Louis, MO2.94MShares$1.59 Million20.39% of portfolio
-
Carlyle Group Inc. Washington, DC2.9MShares$1.56 Million0.18% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.61MShares$1.41 Million0.04% of portfolio
-
Abingworth LLP London, X01.79MShares$967,9590.65% of portfolio
-
Acadian Asset Management LLC Boston, MA1.37MShares$738,7180.0% of portfolio
About SPRUCE BIOSCIENCES, INC.
- Ticker SPRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,560,200
- Market Cap $12.7M
- Description
- Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...